Editor-in-Chief Fabrice Andre 150wide
Professor Fabrice André Villejuif, France
Fabrice André is a medical oncologist working at the Gustave Roussy Institute, Villejuif, France. He is involved in the development of targeted agents in breast cancer including mTOR inhibitors, FGFR inhibitors, PI3K inhibitors, CHK1 inhibitors. He is leading several academic prospective clinical trials that aim at developing personalized medicine for cancer treatment. He is also interested in symptom management and chairs a large epidemiological cohort of 20 000 women with breast cancer. In addition to his clinical research activity, he is chairing a translational research unit focused on biomarker development in several disease areas. He has published more than 150 articles or book chapters.
Declaration of Interests In the past 2 years, participation in advisory boards, and/or speaker at meetings, and/or recipient of travel support for participation in medical meetings for/from:Pfizer, Novartis, Roche, Lilly.
Deputy Editor haller
Professor of Medicine Emeritus Daniel G. Haller, M.D., FACP, FASCO, FRCP; Philadelphia, Pennsylvania, USA
Professor Haller studied at the Syracuse University (BA) and the University of Pittsburgh (MD). After postgraduate training at Georgetown University and two years at the National Cancer Institute, he joined the faculty of the University of Pennsylvania in 1980. His chief areas of clinical research are in the management of gastrointestinal malignancies. He was awarded Deenie Greitzer & Daniel G. Haller, M.D. Professorship in Gastrointestinal Medical Oncology in 2009.
He is a Fellow of ASCO, and has chaired both the Program Committee and the Audit and Finance Committee; he has also been awarded the Distinguished Achievement Award from ASCO. He is an active member of AACR and ESMO. In 2013, he was elected a Fellow of the Royal College of Physicians.
From 2001-2011, Professor Haller served as Editor-in-Chief of the Journal of Clinical Oncology, and is now co-editor of the 4th Edition of the Oxford Textbook of Oncology. He was Editor-in-Chief of ASCO University from 2012-2018. He is the author or co-author of more than 150 peer-reviewed publications.
Declaration of Interests Professor Haller has served as a speaker for TAIHO, Lilly and Amgen
Associate Editors Urogenital tumors Attard
Prof Gerhardt Attard MD PhD FRCP Sutton, UK
Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London. He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute. He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010. His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC). He is an experienced clinical trialist in CRPC and a co-author of more than 130 peer-reviewed manuscripts, including several important papers on advanced prostate cancer. Prof Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010. He received the Cancer Research UK Future Leader Award in 2017. Prof Attard sits on a number of advisory boards and the editorial board of Annals of Oncology.
Declaration of Interests G A was an employee of the Institute of Cancer Research (ICR) up to 8 January 2018; abiraterone acetate was developed at the ICR, which therefore has a commercial interest in the development of this agent.
G A has received:-
Consulting fees and travel support from Janssen-Cilag, Veridex, Roche/Ventana, Astellas, Pfizer, Novartis, Millennium Pharmaceuticals, Abbott Laboratories, Essa Pharmaceuticals and Bayer Healthcare Pharmaceuticals. Speaker’s fees from Janssen, Ipsen, Takeda and Sanofi-Aventis. Grant support from Janssen, AstraZeneca, Arno Therapeutics, Innocrin Pharma and Genentech.
G A is on The ICR rewards to inventors list of abiraterone acetate. G A’s wife has received travel support from Janssen and Astellas.
Gastrointestinal tumors D Arnold
Prof D. Arnold Hamburg, Germany
Dirk Arnold, MD, PhD, is professor of medicine at the University of Hamburg and currently serves as Medical Director of the Asklepios Tumorzentrum Hamburg as well as Head of the Medical Oncology department of AK Altona in Hamburg, one of the center´s major hospitals. He received his training as a medical oncologist and specialist in palliative care at the Martin Luther University Halle-Wittenberg, Halle, Germany. He was assistant professor and chair of the Gastrointestinal Cancer Unit there, and then served as medical director of the University Cancer Center at the University of Hamburg until 2012. From 2012–2015, he was director of the Department of Medical Oncology of the Klinik für Tumorbiologie, University of Freiburg, Germany. In 2016, he joined the Instituto CUF de Oncologia, as medical director of this Cancer Center in Lisbon, Portugal which he still supports as Senior Advisor and Board Member.
Prof. Arnold’s major fields of scientific interest are the treatment of gastrointestinal and genitourinary cancers, focusing on molecular-targeted therapies, immunotherapy, multimodal treatment strategies, and early drug development.
Dr. Prof. Arnold’s major fields of scientific interest are the treatment of gastrointestinal and genitourinary cancers, focusing on molecular-targeted therapies, immunotherapy, multimodal treatment strategies, and early drug development.
Prof. Arnold is a key member of several German and international cancer societies. He is also a board member of the European CanCer Organisation, a board member of the German Society of Hematology and Medical Oncology, and a member of the German Cancer Society. Prof. Arnold is associate editor of Annals of Oncology, and has authored or coauthored more than 190 articles in peer-reviewed journals and several book chapters.
Declaration of Interests In the past 2 years, participation in advisory boards, and/or speaker at meetings, and/or recipient of travel support for participation in medical meetings for/from: Roche, Merck-Serono, Bayer Healthcare, Sanofi, Terumo, Sirtex, Servier, Lilly.
Cervantes
Prof A. Cervantes Valencia, Spain
Andrés Cervantes is Professor of Medicine at the University of Valencia and serves as Head of Section at the Dept. of Hematology and Medical Oncology in the Biomedical Research Institute INCLIVA. He got the Medical Oncology degree at the same institution in 1985. After completing his clinical training, he got a research fellowship at the Free University Hospital in Amsterdam, where he obtained in 1987 his PhD degree with a work on multidrug resistance in the Cellular Pharmacology Lab of this institution. His main areas of research are gastrointestinal and gynaecologic malignancies, phase I trials and new drug development. He has authored many research articles and educational papers published in peer-reviewed journals. He is also the Editor of Cancer Treatment Reviews. He is currently member of the ESMO Executive, as well as of the Educational Steering Committee. He is chairing the Clinical Practice Guidelines Working Group at ESMO. He devotes a significant amount of time to teaching, professional training, and continuing medical education.
Declaration of Interests Dr. Cervantes has acted as a consultant or advisor to Amgen, Astra Zeneca, Sanofi-Aventis, Merck Serono, MSD, Genentech, and Roche.
Tabernero
Dr J. Tabernero Barcelona, Spain
Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology. He is very actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies. He is especially devoted to phase I and II studies with pharmacodynamic endpoints with novel agents directed to the membrane receptors, like the EGFR-family and IGF-1R, the PI3K and ERK signaling pathways, as well as downstream cytoplasmatic and intranucleous effectors like Mdm2/p53 and aurora kinase.
Based in the idea that each tumor has an independent genetic identity, the group he is leading very actively participates in the development of molecular therapies targeting specific oncoproteins, with the purpose of developing personalized therapies (e.g. against EGFR, HER2, BRAF, MEK, PI3K, Akt, mTOR or IGF1-R among others) for those patients displaying genetic lesions or pathway disregulation. One of the main objectives of the group is to identify new predictive markers of response to diverse treatments and to identify markers of primary resistance (de novo) and secondary treatment. At a preclinical level, the group he is leading is developing new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study the tumor development in optimized research models. It also leads a program devoted to the study of circulating biomarkers (detection and genotyping of circulating free DNA).
In addition, Dr. Tabernero is a member of the European Society for Medical Oncology (ESMO), the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO), and different Editorial Boards including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer and Annals of Oncology. He has (co)authored approximately 250 peer-reviewed papers. He has also been a member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.
Declaration of Interests Josep Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Chugai, Genentech, Inc., Genmab A/S, Imugene Limited, Inflection Biosciences Limited, Ipsen, Kura Oncology, Lilly, MSD, Menarini, Merck Serono, Merrimack, Merus, Molecular Partners, Novartis, Peptomyc, Pfizer, Pharmacyclics, ProteoDesign SL, Rafael Pharmaceuticals, F. Hoffmann-La Roche Ltd, Sanofi, SeaGen, Seattle Genetics, Servier, Symphogen, Taiho, VCN Biosciences, Biocartis, Foundation Medicine, HalioDX SAS and Roche Diagnostics.
Josep Tabernero declares institutional financial interest in form of financial support for clinical trials or contracted research for Agendia BV, Amgen SA, Debiopharm International SA, Janssen-Cilag SA, Mologen AG, Novartis Farmacéutica SA, Pharma Mar, Roche Farma SA, Laboratorios Servier SL and Symphogen A/S.
He declares the following non-financial interest:
Senior leadership roles in the following medical societies, research groups and foundations: American Society of Clinical Oncology - ASCO. American Association for Cancer Research - AACR. European Organization for Research and Treatment of Cancer - EORTC. Cancer Core Europe (CCE). Worldwide Innovative Networking (WIN) Consortium in Personalized Cancer Medicine. Spanish Cooperative Gastrointestinal Tumors Group – TTD. Spanish Society for Medical Oncology – SEOM. Spanish Association Against Cancer – AECC. European Academy of Cancer Sciences.
Non-remunerated leadership role in the following Scientific Advisory Boards – Research Institutions: Institute for Biomedical Research (IRB) Bellinzona (2013). IRCC Candiolo Cancer Institute (2013-2017). University Medical Center Utrecht (UMC Utrecht) (2014). Cambridge Cancer Center (2014). Institut Gustave Roussy (2015). German Consortium for Translational Cancer Research (DKTK) (2016). Institute for Health Research INCLIVA- Clinical Hospital of Valencia (since 2011). Spanish National Cancer Research Centre (CNIO) (since 2015). Institute for Health Research of Navarra (IdiSNA) (since 2015). Institute of Cancer Research, Oslo University Hospital (2015-2017). EIT Health (since 2016).
Breast tumors Sotiriou
Dr C. Sotiriou Brussels, Belgium
Dr. Christos Sotiriou earned a medical degree from the Medicine Faculty of the Université Libre de Bruxelles, Belgium, in 1993. He did his internal medicine/oncology residency at the Institut Jules Bordet (Profs. J. Klastersky, M. Piccart), and he earned his specialty in this field in July 1999. From October 1999 till September 2001, he worked as a basic research fellow, at the Division of Clinical Sciences, National Cancer Institute (Pr Edison Liu), National Institutes of Health, Bethesda, MD, USA. After having completed a PhD Thesis at the Université Libre de Bruxelles in September 2004, he became “Chercheur Qualifié” (Research Faculty Member – tenured position) at the National Foundation for Scientific Research (FNRS, Belgium) in 2005. In March 2010, he took over the lead of the Breast Cancer Translational Research Laboratory J-C Heuson. In October 2013, he was appointed “Maître de Recherche” (Senior Research Associate – tenured position) by the National Foundation for Scientific Research (FNRS, Belgium). Dr. Sotiriou is “Chef de Clinique” (Head of clinic), since October 2013, at the Medical Oncology Clinic of the Institut Jules Bordet.
Declaration of Interests A patent on gene expression signatures. In the past 2 years, participation in advisory boards, and/or speaker at meetings, and/or recipient of travel support for participation in medical meetings for/from (in alphabetical order): Amgen, Astellas, AstraZeneca, Bayer, Celgene, Nanostring Technologies, Novartis, Pfizer, Roche.
Thoracic tumors Mitsudomi
Dr T. Mitsudomi Osaka, Japan
Dr. Mitsudomi received his medical degree from Kyushu University, Fukuoka, Japan in 1980, and subsequently completed his residency training in Surgery at Kyushu University Hospital. Dr. Mitsudomi completed his PhD in 1986 and was a visiting fellow at the National Cancer Institute-Navy Medical Oncology Branch, Bethesda, Maryland, USA, from 1989 to 1991. After working at University of Occupational and Environmental Health (1991-1994) and Kyushu University as an associate professor (1994-1995), Dr. Mitsudomi moved to Aichi Cancer Center in 1995 where he was a Vice Director of the hospital and a Chief of the Department of Thoracic Surgery. In 2012, Dr. Mitsudomi became a Professor at the Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka, Japan. His current research interests include surgical treatment of lung cancer and individualized treatment of lung cancer based on cancer genotypes such as EGFR mutations or ALK translocations. He has published more than 250 papers that have featured in international peer-reviewed journals. He is a recipient of Shinoi-Kawai Award from the Japan Lung Cancer Society (2001), JCA–Mauvernay Award from the Japanese Cancer Association (2005) and Mary Matthews Award from the International Association of Study of Lung Cancer (2013).
Declaration of Interests Advisory board: AstraZeneca, Novartis, Chugai, Boehringer-Ingeleheim, Pfizer, Roche, Synta, Lecture fees: AstraZeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Eli-Lilly, Research support: AstraZeneca, Chugai, Boehringer-Ingelheim, Pfizer, Taiho, Ono, Daiichi-Sankyo, Eli-Lilly
Vansteenkiste
Prof J. F. Vansteenkiste Leuven, Belgium
Johan F Vansteenkiste graduated in 1982 from the Catholic University of Leuven before becoming a board-certified specialist in Internal Medicine and Pulmonology. He had additional training in Respiratory Oncology at the European School of Oncology in Milan, Italy, and in Respiratory Endoscopy at the Laser Centre in Marseille, France, before gaining his PhD in Leuven in 1996. He is head of the Respiratory Oncology Unit and its Clinical Trial Unit since 1995, and full professor at the Faculty of Medicine in Leuven. He is an active member of different national and international societies such as ESMO, IASLC, ASCO, ERS, and others. He was Secretary of the Thoracic Oncology Assembly of the ERS and member of the ERS School Board from 2009-2012, member of the Board of Directors of IASLC in 2009-2013, and is a member of the ESMO Lung Educational Group and Guidelines Group. He is the principal investigator or co-investigator in several clinical trials in the area of lung cancer. He was an associate editor for Respiration and Journal of Thoracic Oncology and is a reviewer for several oncology journals. He is author or co-author of more than 200 peer-reviewed papers and book chapters on Respiratory Oncology.
Declaration of Interests Professor Vansteenkiste has research funding at University Hospitals KU Leuven by MSD, was consultant for AstraZeneca, Boehringer Ingelheim, MSD, Novartis, Roche, and Sanofi, and gave lectures for AstraZeneca, BMS, MSD, and Roche.
Head and neck tumors Chan
Prof A. T. C. Chan Shatin, Hong Kong SAR, China
Anthony Chan, Li Shu Fan Medical Foundation Professor of Clinical Oncology, graduated from University College London in 1988 and received postgraduate training in the United Kingdom including the Royal Marsden Hospital where he developed a keen interest in multi-disciplinary clinical and translational research in solid cancers. He joined the Chinese University of Hong Kong in 1993 as Lecturer, becoming Department Chairman in 2002 and Professor of Clinical Oncology in 2006. He has been appointed Director of the Hong Kong Cancer Institute since 2002, Director of the Sir Yue-KongPao Centre for Cancer since 2003, Associate Director of the State Key Laboratory of Oncology in South China since 2006, Associate Dean for External Affairs since 2009, Chief Director of Phase I Clinical Trial Centre since 2013. He is Vice-President of the Hong Kong College of Physicians.
His research has focused on clinical and translational studies in Asia-prevalent cancers, particularly in nasopharynx cancer. Professor Chan has conducted pivotal studies in multimodality treatment approaches in nasopharynx cancer, developed the clinical application of the biomarker EBV DNA and pioneered immunotherapeutic and targeted therapeutics in this disease. He published over 230 peer-reviewed papers, 40 book chapters, and reviews, and delivered over 130 international lectures. He has served on the Editorial Board of the Journal of Clinical Oncology and is currently on the Editorial Boards of International Journal of Cancer, Cancer Science, Oral Oncology and the Chinese Journal of Cancer. He is Faculty member of Oncology, F1000Prime. In January 2014, he will serve as Associate Editor for Annals of Oncology.
Declaration of Interests Professor Chan holds no shares in any drug company or in mutual funds investing exclusively in pharma. He has received study grants from and participated in advisory boards for Amgen, AstraZeneca, Bayer Schering, Boehringer Ingelheim, Eli Lilly, Merck Serono, Novartis, Pfizer, Roche, Sandoz, Sanofi.
Gynecological tumors Monk
Prof B. Monk Phoenix, Arizona, USA
Professor Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine in 1988, and completed a residency in obstetrics and gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in medical genetics and gynecologic oncology. In 1995, Professor Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 until recently, was Associate Professor of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Professor Monk is currently Professor and Director in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. Professor Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix.
Professor Monk’s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer and his paper in the New England Journal of Medicine led to the global approval of anti-VEGF therapy in recurrent cervical cancer. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Professor Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer and is on the Board of Directors for the GOG Foundation, Inc. and is the Cervix Chair for NRG Oncology.
Professor Monk is a fellow of the American College of Surgeons (ACS), the American College of Obstetricians and Gynecologists (ACOG) and the American Society for Colposcopy and Cervical Pathology (ASCCP), as well as being an active member of the Society of Gynecologic Oncology (SGO), American Society of Clinical Oncology (ASCO) and other professional organizations. He has authored more than 235 peer-reviewed articles along with 30 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life.
Declaration of Interests Consultant or advisory role: Merck, TESARO, Roche/Genentech, AstraZeneca, Gradalis, Advaxis, Verastem, Cerulean, Amgen, Vermillion, ImmunoGen, Pfizer, Bayer, NuCana.
Honoraria for presentations: Roche/Genentech, AstraZeneca, Myriad.
Pignata
Dr S. Pignata Naples, Italy
Sandro Pignata was born in Naples in 1962. He took the MD degree in 1986 at the Naples University and the PhD degree in Gastroenterological Science at the University of Rome in 1990. Since 1993 he is in Staff at the National Cancer Institute in Naples, where now is the chief of the Uro-Gynecological Department. Dr. Pignata is the president of the Multicenter Italian Trial in Ovarian cancer (MITO) group that is involved in several randomized trials on the treatment of gynaecological cancer, whose results have been published in important international journals. He i a member of the educational committee of ESMO and of the executive board of the European Network of Gynaecological Oncological Trial Groups (ENGOT) and of the Gynecologic Cancer InterGroup (GCIG).
Declaration of Interests Dr Pignata has received Honoraria from AZ, Roche, Clovis, Tesaro, Pfizer, MSD, Merck, Pharmamar. Funding from Roche and AZ.
Melanoma Long
Prof G. Long Sydney, Australia
Professor Georgina Long, BSc PhD MBBS FRACP, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is the principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground-breaking research, Professor Long has received a number of awards, including the prestigious Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research in 2016, and a number of recent CINSW Premier’s Awards for Outstanding Cancer Research: In 2014, she was awarded the Wildfire Award for the most highly-cited, original, peer-reviewed article published in 2011; and in 2013 she was named the Outstanding Cancer Research Fellow. She is the author of over 160 peer-reviewed publications in clinical and translational research in melanoma since 2011, including the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 120 occasions. She is President-elect for the prestigious international Society for Melanoma Research (President from 2018), is member (2015-2017) and Chair (2016) of the ASCO Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.
Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.
Declaration of Interests Consultant advisor to Amgen, Array pharmaceuticals, BMS, MERCK MSD, Novartis, Pierre-Fabre, Roche.
Hematological malignancies Tsukasaki
Prof K. Tsukasaki Saitama, Japan
Prof Tsukasaki has a Medical Doctor degree (1984) and, after learning Hematology and late effect of atomic bombing, a Doctor in Medicine degree from Nagasaki University (1995). He was a research fellow at Cedars Sinai Medical Center in Los Angeles. He was a member of ATL (Adult T-cell leukemia-lymphoma) Preventing Program which consisted of screening pregnant women for anti-HTLV-1 Ab and recommending the HTLV-1 positive women refraining from breast feeding in Nagasaki prefecture. He was the primary investigator of the International Consensus Report on the management of ATL and is a Professor of the Hematology Department of the International Medical Center in Saitama Medical University. His specialities and research interests include Cancer Clinical Trials, Multi-Step Leukemogenesis including Viral Leukemogenesis, Molecular Targeting Therapy and Tumor Immunology.
Declaration of Interests Participated in trials sponsored by pharmaceutical companies as Kyowa-Hakko/Kirin, GlaxoSmithkline, Celgene, Rosch and MundyPharma; served on advisory boards of Takeda Bio.
Supportive care Jordan
Prof K. Jordan Heidelberg, Germany
Prof. Karin Jordan graduated from Martin Luther University of Halle-Wittenberg, Germany. Following a number of posts at the University Hospital, Halle, and Bernward Hospital, Hildesheim, she was appointed as a specialist in internal medicine and Haematology and Oncology at the University of Halle-Wittenberg. Since 2017 she is the leading senior physician of the Department of Haematology and Oncology at the University Hospital in Heidelberg, Germany. She has been the vice executive director of the ethics committee at the University of Halle from 2009-2015. Dr Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel 2009 and 2015, and is in the ASCO antiemetic guideline panel. She holds the co-chair of Supportive Care study group within the German Society of Medical Oncology (AIO) and is the associate chair of the German Association of Supportive Care in Oncology, Rehabilitation and Social Medicine (ASORS). Dr. Jordan was also a member of the ESMO Young Oncologist Committee. Since 2013 she is the coordinator of the S3 Guidelines on Supportive Care within the Oncology Guideline Program of the German Cancer Society. Since 2014 she is associate editor of “Annals of Oncology” and she is the chair of the ESMO Faculty group of “Supportive and palliative Care” and also the ESMO guideline chair for the section supportive Care since 2017. She has authored and co-authored more than 120 publications and her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.
Declaration of Interests Dr. Jordan holds no shares in any drug company. She has received study grants, honoraria for consultancy and/or is on the speaker bureau of MSD, Merck, Amgen, Hexal, Riemser, Tesaro, Helsinn, Kreussler, Voluntis.
Epidemiology Boffetta
Prof P. Boffetta New York, New York, USA
Professor Boffetta received a Medical Degree from the University of Turin, Italy and a Master in Public Health from Columbia University in New York. Presently, he is Bludhorn Professor of International Community Medicine, and Associate Director for Global Oncology of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai in New York, USA, as well as Professor in the Department of Medical and Surgical Sciences of the University of Bologna, Italy. He is also Adjunct Professor at Harvard T.H. Chan School of Public Health in Boston, USA, Vanderbilt-Ingram Cancer Center in Nashville, USA and Arnold School of Public Health of University of South Carolina in Columbia, USA. He is editor of 15 books and author of over 1250 peer-reviewed scientific publications. Professor Boffetta’s main fields of interest include cancer epidemiology and the risk related to tobacco, alcohol, diet, tobacco, and occupational or environmental exposures, molecular cancer epidemiology, and cancer prevention.
Declaration of Interests Consultant to governmental agencies and private stakeholders on issues and projects on cancer epidemiology and prevention. Expert witness in litigation for plaintiffs and defendants.
Lagiou
Prof P. Lagiou Athens, Greece
Professor Lagiou is Professor of Hygiene and Epidemiology at the School of Medicine, National and Kapodistrian University of Athens, Greece and Adjunct Professor of Epidemiology at the Harvard T.H. Chan School of Public Health. She has a medical degree and is board-certified in Internal Medicine. She also holds a Master’s of Science and a Doctoral degree in Epidemiology. She has served as Foreign Adjunct Associate Professor of Epidemiology at the Karolinska Institutet in Sweden and as Fellow of the Bureau of Epidemiologic Research in the Academy of Athens, Greece. She has co-authored more than 370 peer reviewed publications, a textbook of epidemiology (in Greek), as well as chapters in several books, and she is co-editor of a soon to be published textbook of cancer epidemiology. Professor Lagiou’s main fields of interest include the nutritional and endocrine epidemiology of cancer, and cancer prevention.
Declaration of Interests Professor Lagiou has declared no conflicts of interest.
Sarcoma and clinical pharmacology Mir
Dr O. Mir Villejuif, France
Olivier Mir, MD, PhD, MPH is a medical oncologist and clinical pharmacologist in Gustave Roussy Cancer Institute, University of Paris-Sud. Dr. Mir trained as a medical oncologist and clinical pharmacologist at University Paris Descartes, and obtained the Silver medal (highest degree) from Paris Medical School in 2009. Dr. Mir is currently member of Breast and Sarcoma Groups at Gustave Roussy Cancer Institute in Paris, and is an active member of the French Sarcoma Group (GSF-GETO), Francilian Onco-Geriatry Group (FROG), EORTC Soft Tissue and Bone Sarcoma Group, and French Group on “Cancer in pregnancy” (CALG). His main research interests are: sarcoma/GIST, anti-VEGF agents, early drug development, pregnancy-related neoplasms, and geriatric oncology. He is also involved in translational research aspects related to precision medicine and pharmacokinetics notably in sarcoma/GIST, and pregnancy-related neoplasms (INSERM unit CIC-P 0901, Prof JM Treluyer, Paris Descartes University). Dr. Mir has contributed to over 100 peer-reviewed medical publications.
Declaration of Interests Honoraria: Astra-Zeneca, Amgen, Bayer Healthcare, Blueprint Medicines, BMS, Eli-Lilly, Incyte, Ipsen, Lundbeck, MSD, Novartis, Pfizer, PharmaMar, Roche, Servier, Vifor Pharma, Prime Oncology, Netcancer.net, GLC consulting, TBWA.
Stocks: Amplitude Surgical, Transgene, Netcancer.net.
Non-financial interests/not remunerated: Non-remunerated speaker for Medscape, Member of the editorial board of J Clin Oncol (ASCO), Speaker for SPAEN (Sarcoma PAtients EuroNet).
Other: Associate editor for Annals of Oncology (ESMO)
Preclinical and experimental science Helleday
Prof T. U. E. Helleday Sheffield, UK
Thomas Helleday is the Söderberg Professor of Translational Medicine and Chemical Biology at Karolinska Institutet, Stockholm, Sweden heading the division of Translational Medicine and Chemical Biology located at Science for Life laboratories. Thomas Helleday started his own independent research groups at the Institute for Cancer Studies, University of Sheffield, UK in 2000, only a year after completing a PhD in Genetic Toxicology and a separate BSc in Business Administration and Economics. At the age of 35 years old he was already installed as professor at three Universities; Stockholm University, University of Sheffield and at the University of Oxford.
Professor Helleday heads a multidisciplinary translational research group focusing on understanding basic DNA repair and DNA-damage signaling pathways at replication forks and developing novel drugs for anti-cancer treatments. The group was first to demonstrate a novel concept for treating cancer called “synthetic lethality” established by the selective killing of BRCA mutated breast and ovarian cancers by PARP inhibitors. The research group is currently divided into teams focusing on basic science, biology, biochemistry, in vitro assays, medicinal chemistry and in vivo pharmacology. The work is focussed on bench to bedside and the group motto is ‘turning cancer defects into cures’. Professor Helleday has been awarded numerous eminent international grants and awards in recognition of his research accomplishments including the Eppendorf-Nature Young European Investigator Award (2005) for outstanding contribution within the field of biomedical science by the journal Nature and the prestigious ERC advanced grant (2010). He is currently been awarded a total of about EUR 15 million in research grants.
Declaration of Interests Receipt of Honoraria or Advisory roles: Sierra Oncology, Oxcia AB
Stock Options/Shareholder: Oxcia AB (co-founder).
Other: Founder and chairman of Helleday Foundation. Receives royalty from PARP inhibitor sales.
Precision medicine Swanton pic
Prof C. Swanton London, UK
Professor Swanton completed his PhD in 1998 at the Imperial Cancer Research Fund Laboratories on the UCL MBPhD program before completing his medical oncology and Cancer Research UK funded post-doctoral clinician scientist training in 2008. Charles was appointed Medical Research Council and Cancer Research UK senior clinical research fellow and Group Leader of the Translational Cancer Therapeutics laboratory at the CR-UK London Research Institute in 2008 focusing on personalised cancer medicine through an understanding of mechanisms of drug resistance, intratumourheterogeneity and genomic instability. He combines his laboratory research with clinical duties focused on biological mechanisms of drug resistance in lung and breast cancer.
Charles worked as a consultant medical oncologist at the Royal Marsden Hospital with an interest in early phase drug development for the treatment of specific subtypes of metastatic solid tumours (2008-2011). Charles has had the lead and corresponding author publications in Nature, Cancer Cell, PNAS, Lancet Oncology and The New England Journal of Medicine. Charles is a member of several translational research scientific committees including the Cancer Research UK Sciences Committee and ESMO translational working group. He leads the scientific aspects of the EU Framework Program 7 PREDICT consortium. According to Thomson Reuters, his paper in NEJM in 2012 was the most highly cited in biomedicine in 2012. Charles was made Fellow of the Royal College of Physicians in April 2011 and was appointed to the Chair in Personalised Cancer Medicine at the University College London Cancer Institute and Consultant Medical Oncologist at UCL Hospitals, Thoracic Oncology Unit in November 2011. Charles is the Chief Investigator of the CR-UK TRACERx national lung cancer evolution study to decipher clonal evolution through the disease course and is director of the CR-UK UCL Lung Cancer Centre. Charles was recently promoted to the tenured position of Senior Group Leader at the CR-UK London Research Institute and was awarded the Royal College of Physicians Goulstonian lecture and Graham Bull Prize for Clinical Sciences in 2013.
Declaration of Interests Receipt of Grant/Research Support: Pfizer, AstraZeneca, BMS, Ventana
Receipt of Honoraria or Consultation Fees: Boehringer Ingelheim, Eli Lily, Servier, Novartis, Roche-Genentech, GlaxoSmithKline, Pfizer, BMS, Celgene, AstraZeneca, Illumina
Stock Options/Shareholder: Apogen Biotechnologies, Epic Bioscience, Grail, and has stock options and is co-founder of Achilles Therapeutics.
Bioinformatics McGranahan/
Dr N. McGranahan London, UK
Dr. Nicholas McGranahan completed his undergraduate degree in Natural Sciences, specializing in Evolutionary Genetics, at the University of Bath before pursuing post-graduate studies at University College London at the Centre of Mathematics and Physics in the Life Science and Experimental Biology (CoMPLEX). In 2011, Dr. McGranahan joined Professor Charles Swanton’s group at the CR-UK London Research Institute (now the Francis Crick Institute), completing a PhD in Cancer Genomics in 2015.
As a Senior Research Associate on the CR-UK TRACERx (TRAcking Cancer Evolution through therapy (Rx)) lung cancer study, Dr McGranahan’s research interests include using bioinformatics to dissect cancer genome evolution and the mechanisms of drug resistance, intra-tumour heterogeneity and genomic instability. His work involves exploring the evolutionary history of cancers through sequencing multiple regions of individual tumours. In particular, Dr McGranahan’s research has focused on understanding the importance of genome doubling in tumour evolution, as well as exploring the mutational processes shaping the genomes of cancers over space and time. Dr McGranahan has authored over 20 articles in high impact journals, including first author publications in Science, Nature and Cancer Cell.
Declaration of Interests Consultancy work for Achilles Therapeutics.
BioTechnologies Mardis
Prof E. Mardis Columbus, Ohio, USA
Elaine Mardis, PhD is co-Executive Director of the Institute for Genomic Medicine at Nationwide Children’s Hospital and the Nationwide Foundation Endowed Chair of Genomic Medicine. She also is Professor of Pediatrics at The Ohio State University College of Medicine. Professor Mardis joined Nationwide Children’s Hospital in 2016. Educated at the University of Oklahoma with a B.S. in Zoology and a Ph.D. in Chemistry and Biochemistry, Professor Mardis did postgraduate work in industry at BioRad Laboratories. She was a member of the faculty of Washington University School of Medicine from 1993-2016.
Professor Mardis has authored over 350 articles in prestigious peer-reviewed journals and book chapters in several medical textbooks. Professor Mardis was awarded the Morton K Schwartz award from the American Association for Clinical Chemistry in 2016, and received the Docteur Honoris Causa from Université d’Evry Val d’Essonne, Paris in 2018. Professor Mardis has been a member of the American Association for Cancer Research (AACR) since 2007, was the program committee chair for the 2018 AACR Annual Meeting and is the AACR President-elect. She serves as a member of the Supervisory Board of Qiagen, N.V, for which she receives monetary compensation and stock shares. Professor Mardis serves on the scientific advisory boards of PACT Pharma (Hayward, CA) and Interpreta, LLC (La Jolla, CA) for which she receives monetary compensation and stock options. She also serves in a scientific advisory capacity to The Mark Foundation for Cancer Research, to Genome Canada (Science and Industry Advisory Council member), to the Ontario Institute of Cancer Research (Toronto), to the British Columbia Genome Sciences Centre’s Precision OncoGenomics (POG) Program, and to Canada’s Genomics Enterprise (cGEN), for which she receives honoraria.
Declaration of Interests Professor Mardis has declared no conflicts of interest.
Onco-Immunology Ascierto
Dr P. Ascierto Naples, Italy
Dr. Paolo A. Ascierto is the Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the Istituto Nazionale Tumori Fondazione G. Pascale in Naples, Italy. He received his medical degree from the University of Naples, where he earned board certification in oncology. Before his present position at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy of the National Tumor Institute, he previously served there as a postdoctoral fellow and then vice-director of the Department of Clinical Immunology.
Dr. Ascierto’s primary research interests have included research in the genetics and proteomics of melanoma, assessment of new molecular markers for tumor progression, biochemical and immunological monitoring, immunotherapy and vaccination treatments in solid tumors, and combination startegies with I-O. He has served as principal investigator in numerous clinical trials mainly with I-O, and has been well-published in peer-reviewed journals on topics related to his research interests (he has published more than 300 articles or book chapters).
He has also been an invited speaker at more than 400 national and international conferences and meetings, and maintains active memberships in several international medical societies.
Declaration of Interests Dr. Ascierto has a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte, Newlink Genetics, Genmab, Medimmune, Syndax, AstraZeneca. He also received research funds from for Bristol Myers Squibb, Roche-Genentech, and Array.
Neuro-oncology Idbaih
Dr A. Idbaih Paris, France
Ahmed Idbaih, MD, PhD, is neuro-oncologist in University Hospital La Pitié-Salpêtrière in Paris, France. He received his MD from Université Pierre et Marie Curie/ Sorbonne Université in Paris in 2004. He is trained in clinical neurology and clinical oncology in Paris. In parallel to his clinical training, he received his M.Sc and Ph.D. from Université Paris XI in 2007 in the field of molecular oncology. After a two years-post-doctoral fellowship in Dana Farber Cancer Institute, in Boston, he came back to University Hospital La Pitié-Salpêtrière. He is Maitre de Conférences-Praticien Hospitalier since 2013. He is focused on medical management of primary brain tumor patients. He is interested in clinical research and translational research in neuro-oncology. He participates to several clinical trials enrolling brain tumor patients and he coordinates a group dedicated to experimental therapeutics in neuro-oncology. He (co)-authored more 140 papers.
Declaration of Interests Doctor Ahmed Idbaih has received study grants from Carthera, Beta Innov, Sanofi, Hoffmann-La Roche, participated in advisory boards for Hoffmann-La Roche, Bristol Myers Squibb and participated to Continuing Medical Education funded by Cipla
Molecular and surgical pathology Wistuba
Prof I. I. Wistuba Houston, Texas, USA
Ignacio I. Wistuba, M.D., is Professor and Chair of the Department of Translational Molecular Pathology, Division of Pathology & Laboratory Medicine, M.D. Anderson Cancer Center at Houston, Texas, United States. He is also Professor of Thoracic/Head and Neck Medical Oncology and Director of the Thoracic Molecular Pathology Laboratory. Professor Wistuba earned his medical degree in 1985 from the Austral University of Chile in Valdivia and trained in surgical pathology in the Catholic University of Chile in Santiago. He furthered his training in the United States at The University of Texas Southwestern Medical Center as a postdoctoral fellow in lung cancer molecular pathology research at the Hamon Center for Therapeutic Oncology Research Center. In 2003, he joined MD Anderson as Associate Professor of Pathology and Thoracic/Head and Neck Medical Oncology. In 2008 he was promoted to Professor, in 2010 was named the Jay and Lori Eisenberg Professor, and in 2013 named Anderson Clinical Faculty Chair for Cancer Treatment and Research.
Professor Wistuba is a specialist in lung cancer surgical and molecular pathology. He has a strong record of scientific achievement in the study of lung cancer, which includes more than 300 peer-reviewed papers and several book chapters. His research interests include the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer, and the identification of novel molecular targets and validation of biomarkers for targeted therapy. His research is funded by grants from NIH/NCI, Cancer Prevention Research Institute of Texas (CPRIT), V Foundation and the U.S. Department of Defense in addition to research agreements with pharmaceutical and biotechnology companies. Professor Wistuba oversees biomarker studies for lung cancer therapeutic clinical trials, including the MD Anderson BATTLE program, and he is leader of the MD Anderson Cancer Center Support Grant (CCSG) Tissue Biorepository and Pathology Resources (TBPR).
He currently serves as the pathologist of the Lung Cancer Committee for the Southwestern Oncology Group (SWOG), the Lung Cancer Mutation Consortium (LCMC), and member of the Pathology Panel of the International Association for the Study of Lung Cancer (IASLC). He is also member of the American Association of Oncology (ASCO) Research Committee. He serves as senior editor of Cancer Prevention Research and on the Editorial Boards of Clinical Cancer Research, Annals of Diagnostic Pathology, Archives of Pathology and Laboratory Medicine, and the Journal of Clinical Oncology.
Declaration of Interests Professor Wistuba is currently conducting research sponsored by Genentech, Inc., Myriad, Inc., Oncoplex, Merck, and Bayer. He has also received honoraria from GlaxoSmithKline, Genentech/Roche, Ventana, General Electric, Pfizer, Boehringer-Ingelheim, and Lilly.
Early Drug Development Massard
Dr C. Massard Villejuif, France
Christophe Massard (MD, PhD) medical oncologist, is Chairman of Early Drug Development multidisciplinary tumor board (RCP-150) and, Chair Drug Development Department (DITEP), Gustave Roussy, Villejuif, France. He is Consultant Medical Oncologist, half time at Drug Development department (DDD) and half time at Department of Medical Oncology (GU cancer team), and joined the faculty in 2006. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a special interest in Genito urinary cancer and Central Nervous System.
Dr Massard received his medical degree from PARIS XI University in 2006, and he got a MSc and PhD from PARIS XI University in 2013. He completed his residency training in Paris Hospital, followed by his fellowship in medical oncology at Gustave Roussy. He is board- certified in Medical Oncology. He did a post-doctoral fellowship in Prof DeBono’s lab at the Royal Marsden Hospital of London and Institute of Cancer Research (London).
Dr Massard is member of ESMO, ASCO, AACR. Over the last 5 years, he was the principal investigators of 15 phase I trials, 1 phase II trial (prostate cancer), and subinvestigator of more than 80 clinical trials (phase 1 trials and GU cancers). He is also involved in translational research aspects related to precision medicine(MOSCATO, MATCH R and PETRUS program). Dr Massard has contributed to over 100 peer-reviewed publications, including publications in European Urology, Annals of Oncology and Journal of Clinical Oncology.
Research axes: early clinical trials, precision medicine, GU cancers (prostate cancer, bladder cancer and testis), glioma, and circulating biomarkers.
Declaration of Interests Participation to advisory boards, speaker investigator for: Amgen, Astellas, Astra Zeneca, Bayer, Celgene, Genentech, Ipsen, Jansen, Lilly, Novartis, Pfizer, Roche, Sanofi, Orion.
Industry Corner: Perspectives and Controversies Dhingra
Dr K. Dhingra New York, New York, USA
Dr. Kapil Dhingra is Managing Member, KAPital Consulting LLC, a healthcare consulting firm that he founded in 2008 to provide oncology-related strategic consulting for novel diagnostics and therapeutics. Dr. Dhingra received his MBBBS degree from the All India Institute of Medical Sciences, New Delhi, India. He completed Internal Medicine residency at Lincoln Hospital in New York followed by Hematology-Oncology fellowship at Emory University, Atlanta. From 1989-1996, he was an academic faculty member at MD Anderson Cancer Center in Texas where he pursued translational laboratory research and clinical research. His laboratory research focused on detection of minimal residual disease in CML and on study of early molecular alterations in breast cancer. His clinical trials largely focused on the emerging field of biological therapy. He joined Eli Lilly and company in Indianapolis in 1996 where he directed the clinical development of SERMs and hormonal therapy drugs for prostate cancer. From 1999-2008, he worked at Roche oncology where he played a leadership role in the development of a number of important cancer drugs, including Herceptin, Rituxan, Tarceva, Avastin, and, Zelboraf. He was Vice President and Head, Oncology Clinical Development from 2002-2008.
Throughout his industry career, he maintained a faculty appointment, initially at Indiana University School of Medicine and, subsequently, at Memorial Sloan-Kettering Cancer Center, New York. He has authored or co-authored more than 100 publications and abstracts. He was a member of the Board of Directors of SARC consortium from 2009-2013. He currently serves on the NCI Experimental Therapeutics Special Emphasis panel, International Scientific Advisory Board of Institut Gustave Roussy, and, on the Product Development Review Committee of Cancer Prevention and Research Institute of Texas.
Declaration of Interests Dr. Dhingra serves on the Board of Directors and/or Scientific/Clinical Advisory Boards of a number of companies and non-profit organizations. Present Board of Director appointments include Exosome Diagnostics (Chairman), Algeta (acquired by Bayer), Median Technologies (France), Epitherapeutics (Denmark), Advanced Accelerator Applications (France), and, Autolus (UK). Previously he served on the BoD of Algeta (acquired by Bayer), YM Biosciences (acquired by Gilead), Micromet (acquired by Amgen), and, Biovex (acquired by Amgen), among others.
Liaison with ESMO Garrido
Dr. P. Garrido Madrid, Spain
Pilar Garrido is Associate Professor of Medical Oncology at Universidad de Alcalá (Madrid, Spain) and serves as Head of the Thoracic Tumours Section in the Medical Oncology Department at the University Hospital Ramón y Cajal (IRYCIS) in Madrid, Spain. Co-director of the Cancer and Chronic Disease Research Group at Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), her main areas of research and clinical interest are thoracic tumours, in particular lung cancer, having authored many research articles published in peer-reviewed journals.
Member of the ESMO Council as Chair of the Press & Media Affairs Committee, she is also currently involved as member of the ESMO Fellowship Committee, Women For Oncology Committee, ESMO Faculty for lung and other thoracic tumours and IASLC Bylaws Committee.
Former president of the Spanish Medical Oncology Society, she currently serves on a variety of national scientific committees including the Spanish National Cancer Strategy Committee. Actively involved in training, she is currently President of the Spanish National Advisory Council for Health Science Specialist Training as well as President of the Medical Oncology Specialist Training Committee.
Declaration of interests Dr Garrido has acted as a speaker and in an advisory role for Roche, MSD, BMS, Boeringher-Ingelheim, Pfizer, and Astra Zeneca. In addition she has also acted in an advisory role for Abbvie, Guardant Health, Novartis, Lilly, Janssen, Sysmex, Blue print and Takeda.
Methodology Lisa Belin
Lisa Belin Lisa Belin is a biostatistician, she was graduated from the French national statistical engineer school (ENSAI, Rennes) in 2009 and she defended her PhD in 2016 working on single arm phase II designs using a time-to-event endpoint. This topic was particularly relevant in immunotherapy and targeted agents’ evaluations. After seven years working at the Institut Curie in Paris, she joined the Biostatistics and Public Health department of University Hospital La Pitié-Salpêtrière in Paris, France. She was involved in several national and European projects on gynecological and breast cancer trials. She worked on SHIVA trial data and was interested in precision medicine evaluation. Since she joined University Hospital La Pitié-Salpêtrière she developed skills in neuro-oncology. Her research topic is early phase trial and precision medicine evaluation. She was involved in more than 30 clinical trials methodology.
Biostatistics, clinical research, early phase trial, time-to-event endpoint, breast cancer, neuro-oncology
Declaration of interests Lisa Belin has declared no conflicts of interest.
Diana Giannarelli
Diana Giannarelli Diana Giannarelli is a biostatistician working at the Regina Elena National Cancer Institute since 1984. She is also an Adjunct Professor of Statistical Methodology at the University of Rome – La Sapienza.
Since 2004 she has been involved in the Regional Ethics Committee of Lazio as the Biostatistical expert and since October 2018 in the Dulwich Research Ethics Committee in London.
At the Regina Elena National Cancer Institute (the Comprehensive Cancer Centre in Rome) she is the Director of the Clinical Trial Center which includes the Biostatistical Unit, the pool of Data Managers and Research Nurses and the Technical-Scientific Secretariat of the Ethics Committee which coordinates the activities of all the Research Centres in the Region.
As a biostatistician she is involved in clinical trial design in all drug development phases and in real life context. Main fields of analysis regards prognostic/predictive biomarkers discovery and validation, meta-analyses, innovative approach to survival models and reduction of high-dimensional matrix.
Her bibliographic profile consists of more than 370 papers on peer-reviewed journals, with an H-index of 53 and more than 10000 citations (Scopus).
She was also a reviewer for the European Call EraCosSysMed- 2 (European Research Projects on Systems Medicine (JTC-2)), for the ERA-Net TRANSCAN-2 (Transalation Research on rare cancers (JTC2017)) and for the ERAPerMed Call 2019.
Phase I-IV trial design, Prognostic/ predictive factors models: development and validation, Survival analysis, Meta-analyses, Real world evidence
Declaration of interests Diana Giannarelli has declared no conflicts of interest.
Axel Hinke
Dr. Axel Hinke Düsseldorf, Germany
Axel Hinke received his PhD from the Faculty of Science, University of Düsseldorf, in 1981. Until 1991 he worked at the medical departments of German subsidiaries of the Swedish pharmaceutical companies LEO and Pharmacia AB, finally heading the clinical research program (oncology), clinical trial services and biostatistics.
In 1991, Dr Hinke founded WiSP Wissenschaftlicher Service Pharma GmbH, an independent contract research institute, predominantly active in the design, organisation and analysis of cancer clinical trials, especially in cooperation with academic/cooperative clinical research groups, as those within the German Cancer Society (AGO, AIO, ARO, AUO, ADO). In parallel, he established the data centre of the Uro-oncological working group of the German Cancer Society at Essen University. After retiring as managing director of WiSP in 2013, he continues to work as a consultant and lecturer within the framework of academic cancer study projects and education. He is steering committee member of the AIO Quality of Life Working Group. Dr Hinke is biostatistical co-author of more than 100 articles published in major medical journals.
Biostatistics and methodology of cancer trials in all phases of clinical development; analysis of PRO data.
Declaration of interests Honoraria for lectures on biostatistics from Roche, Sanofi and Amgen.
Victor Moreno
Prof V. Moreno Barcelona, Spain
Victor Moreno, MD, PhD, is professor of preventive medicine at the University of Barcelona and director of the Oncology Data Analytics Program at the Catalan Institute of Oncology, Barcelona, Spain. He received his PhD in clinical pharmacology studying sequential statistical methods to improve efficiency of epidemiological studies and clinical trials. Then he spent a postdoc at the International Agency for Cancer Research in Lyon, where he started working in cancer epidemiology and prevention. He has been researching in cancer epidemiology and statistical methods at the Catalan Institute of Oncology since its creation in 1995, with a joint position at the Autonomous University of Barcelona from 1991-2005 and at the University of Barcelona since 2006, where he has been teaching biostatistics to medical students.
Prof. Moreno major field of scientific interest in addition to statistical methods is genetic and molecular epidemiology of colorectal cancer (CRC). He has designed and conducted several case-control studies on CRC and contributed to the identification of genetic susceptibility loci, and molecular mechanisms involved in CRC etiology and progression. The Oncology Data Analytics Program that he leads performs research in bioinformatics for precision oncology, cancer outcomes, machine learning, and studies on biomarkers for diagnosis, prognosis and prediction.
Colorectal cancer, genetic epidemiology, molecular epidemiology, biomarkers, prognosis, diagnosis, biostatistics, risk models, classification, prediction, network analysis, sequential analysis, cancer subtypes, bioinformatics, transcriptomics, epigenetics, micro-RNA, GWAS
Declaration of interests Dr. Moreno has been consultant to Bioiberica S.A.U. and Grupo Ferrer S.A., he has received research funds from Universal DX and is co-investigator in grants with Aniling.
Editor's Emeriti F. Cavalli Bellinzona, Switzerland
D. J. Kerr Oxford, UK
J.-C. Soria Gaithersburg, Maryland, USA
J. B. Vermorken Edegem, Belgium
Editorial Board M. S. Aapro, Genolier, Switzerland
M. Alsina, Barcelona, Spain
Y. Ando, Nagoya, Japan
I. Barnes, Oxford, UK
J. Bellmunt, Boston, Massachusetts, USA
B. Besse, Villejuif, France
J. Beyer, Zurich, Switzerland
P. Bierman, Omaha, Nebraska, USA
J.-Y. Blay, Lyon, France
C. Bokemeyer, Hamburg, Germany
N. Boku, Tokyo, Japan
E. Bria, Verona, Italy
E. F. Burgess, Charlotte, North Carolina, USA
P. G. Casali, Milan, Italy
F. Ciardiello, Naples, Italy
A. Comandone, Turin, Italy
P. G. Corrie, Cambridge, UK
J. Corts, Madrid, Spain
G. Curigliano, Milan, Italy
A. Di Leo, Prato, Italy
R. Dienstmann, Barcelona, Spain
T. Dorff, Los Angeles, California, USA
H. Dosaka-Akita, Sapporo, Japan
A. Eniu, Cluj-Napoca, Romania
S. Galbraith, Cambridge, UK
G. Giamas, Brighton, UK
B.-C. Goh, Singapore, Singapore
A. Goldhirsch, Milan, Italy
P. Grimison, Sydney, Australia
A. Grothey, Rochester, Minnesota, USA
S. Halabi, Durham, North Carolina, USA
D. M. Hyman, New York, New York, USA
K. Hotta, Okayama, Japan
I. Hyodo, Tsukuba, Japan
M. Ignatiadis, Brussels, Belgium
D. H. Ilson, New York, New York, USA
H. Iwata, Aichi, Japan
F. Janku, Houston, Texas, USA
N. Katsumata, Kawasaki, Japan
N. Kiyota, Kobe, Japan
C. La Vecchia, Milan, Italy
P. N. Jr Lara, Sacramento, California, USA
J. M. Larkin, London, UK
S. Loi, Melbourne, Australia
S. Loibl, Neu-Isenburg, Germany
F. Lordick, Leipzig, Germany
Y. Loriot, Villejuif, France
D. Lorusso, Milan, Italy
T. Macarulla Mercade, Barcelona, Spain
M. Martin Jimenez, Madrid, Spain
S. Matsui, Tokyo, Japan
J. Maurel, Barcelona, Spain
G. McArthur, Melbourne, Australia
F. Meric-Bernstam, Houston, Texas, USA
S. Michiels, Villejuif, France
H. Minami, Kobe, Japan
T.S.K. Mok, Shatin, Hong Kong
Y. Nishimura, Osaka-Sayama, Japan
K. Nishio, Osaka-Sayama, Japan
S. Novello, Turin, Italy
M. Ogura, Gifu, Japan
A. Ohtsu, Kashiwa, Japan
I. Okamoto, Fukuoka, Japan
S. I. Ou, Orange, California, USA
C. Pezaro, Melbourne, Australia
P. Pfeiffer, Odense, Denmark
S. Postel-Vinay, Villejuif, France
A. Psyrri, New Haven, Connecticut, USA
D. Quinn, Los Angeles, California, USA
S. S. Ramalingam, Atlanta, Georgia, USA
M. Reck, Grosshansdorf, Germany
B. Rini, Cleveland, Ohio, USA
R. Rosell, Badalona, Spain
A. D. Roth, Geneva, Switzerland
R. Salazar, Barcelona, Spain
M. Scartozzi, Ancona, Italy
N. Schmitz, Hamburg, Germany
H.-J. Schmoll, Halle, Germany
I. Sekine, Tsukuba, Japan
Q. Shi, Rochester, Minnesota, USA
A. F. Sobrero, Genoa, Italy
G. Sonpavde, Birmingham, Alabama, USA
V. Subbiah, Houston, Texas, USA
S. Takahashi, Tokyo, Japan
M. Toi, Kyoto, Japan
N. Turner, London, UK
Y.-L. Wu, Guangzhou, China
J. C.-H. Yang, Taipei, Taiwan
S. Yano, Kanazawa, Japan
T. Yoshino, Chiba, Japan
A. X. Zhu, Boston, Massachusetts, USA
Executive Editor Lewis Rowett
Cancer Epidemiology Unit University of Oxford Richard Doll Building Roosevelt Drive OXFORD OX3 7LF
Telephone: +44 1865 289688
|
京公网安备 11010802027423号